Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CC chemokine receptor type 3 (CCR3 or CD193)
- Target
- CCR3 or CD193
- Molecular classification
- G protein-coupled receptor (GPCR), Membrane receptor, Chemokine receptor
01
Overview
CC chemokine receptor type 3 is a membrane-bound G protein-coupled receptor primarily expressed on eosinophils, basophils, mast cells, and Th2 lymphocytes. It binds several chemokines—most notably the eotaxin family (CCL11, CCL24, CCL26), MCP-3 (CCL7), MCP-4 (CCL13), and RANTES (CCL5)—to mediate chemotaxis, activation, and accumulation of these cells in sites of allergic inflammation and parasitic infection. CCR3 is implicated in the pathophysiology of asthma, allergic rhinitis, and other chronic inflammatory diseases, as well as serving as a co-receptor for HIV-1 entry into susceptible cells. Despite significant pharmaceutical interest and many small-molecule antagonists developed, no CCR3-based drug has yet achieved clinical success.
- Other names
- CCR3CD193 (Cluster of Differentiation 193)CC motif chemokine receptor 3
02
Mechanism of action
Antagonism of CCR3 blocks its interaction with chemokine ligands (e.g., eotaxins, MCP-3, RANTES), leading to reduced recruitment and activation of eosinophils and other immune cells, with therapeutic potential in allergy and inflammatory diseases.
03
Biological functions
Signal transductionChemotaxis (directs migration of eosinophils, basophils, Th2 lymphocytes)Immune response (involved in allergic inflammation, activation at sites of infection or tissue injury)Acts as co-receptor for HIV-1 entry in certain cell populations
04
Disease associations
Allergy and asthma (main role in eosinophil recruitment in airways, specifically in allergic inflammation)Inflammation (chronic inflammatory disorders)Neurodegenerative diseases (potential involvement via eotaxin signaling, e.g., Alzheimer’s, Parkinson’s)Infection (HIV-1 co-receptor for viral entry)
05
Safety considerations
Therapeutic antagonism may carry risks including immune system modulation, possible increased infection risk, and off-target effects as with other immune modulators.No major clinical success yet; safety concerns mostly theoretical or based on animal models.
06
Interacting drugs
UCB35625 (antagonist)
8 more in the full profile.
07
Biomarkers
Blood levels or tissue expression of eotaxins (CCL11, CCL24, CCL26) are used as markers for allergic inflammation and potentially for neurodegenerative and age-related diseases.CCR3 expression on eosinophils, basophils, and Th2 cells may serve as a biomarker for allergic or inflammatory disease susceptibility/activity.
Beyond the preview
Go deeper on CC chemokine receptor type 3 (CCR3 or CD193).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC chemokine receptor type 3 (CCR3 or CD193).